Literature DB >> 19656559

The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.

Ji-Young Kim1, Jin-Ki Kim, Jeong-Sook Park, Youngro Byun, Chong-Kook Kim.   

Abstract

Tissue plasminogen activator (tPA), a widely used thrombolytic agent, has an application limit due to short half-life. To prolong the half-life of tPA, liposomes composed of egg phosphatidylcholine (EPC), cholesterol (CHOL) and sodium cholesterol-3-sulfate (CS) were prepared by lipid film method. In addition, distearolyphosphatidyl ethanolamine-N-poly(ethylene glycol) 2000 (DSPE-PEG 2000) was included to give steric barrier to liposomes. Physicochemical characteristics such as particle size, zeta potential, entrapment efficiency and long-term storage stability at 4 degrees C were investigated. The fibrinolytic activity of tPA-loaded in liposomes was confirmed by fibrin clot lysis assay. In vivo pharmacokinetic properties of tPA and the effect of PEG on the blood circulation of tPA-loaded in liposomes in circulation were also evaluated. Both conventional liposomes (EPCL) and PEGylated liposomes (EPC-PEGL) were proper as an injectable formulation with small particle size. Loading process of tPA into liposomes did not alter fibrinolytic activity of intact tPA. Encapsulation of tPA into EPCL and EPC-PEGL prolonged half-life of tPA by 16 and 21 folds compared with free tPA, respectively. Therefore, the use of liposomes could prolong the circulation lifetimes and longevity effect of liposomes on tPA was increased by PEG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656559     DOI: 10.1016/j.biomaterials.2009.07.021

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  40 in total

Review 1.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage.

Authors:  Andrzej S Pitek; Jooneon Park; Yunmei Wang; Huiyun Gao; He Hu; Daniel I Simon; Nicole F Steinmetz
Journal:  Nanoscale       Date:  2018-09-13       Impact factor: 7.790

3.  Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Authors:  Shan Liu; Xiaozhou Feng; Rong Jin; Guohong Li
Journal:  Expert Opin Drug Deliv       Date:  2017-09-28       Impact factor: 6.648

Review 4.  Vascular targeting of antithrombotic agents.

Authors:  Ronald Carnemolla; Vladimir R Muzykantov
Journal:  IUBMB Life       Date:  2011-07-15       Impact factor: 3.885

5.  In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.

Authors:  Xing Hua; Lina Zhou; Ping Liu; Yun He; Kaibin Tan; Qinghai Chen; Yuejuan Gao; Yunhua Gao
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

6.  An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.

Authors:  Hoai X Nguyen; Edgar A O'Rear
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

7.  Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.

Authors:  Jun Deng; Heng Mei; Wei Shi; Zhi-Qing Pang; Bo Zhang; Tao Guo; Hua-Fang Wang; Xin-Guo Jiang; Yu Hu
Journal:  Curr Med Sci       Date:  2018-06-22

8.  The bifunctional liposomes constructed by poly(2-ethyl-oxazoline)-cholesteryl methyl carbonate: an effectual approach to enhance liposomal circulation time, pH-sensitivity and endosomal escape.

Authors:  Huan Xu; Wei Zhang; Yan Li; Fei F Ye; Peng P Yin; Xiu Yu; Mei N Hu; Yuan S Fu; Che Wang; De J Shang
Journal:  Pharm Res       Date:  2014-05-08       Impact factor: 4.200

9.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

10.  Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.

Authors:  Hai-jiang Jin; Hao Zhang; Min-li Sun; Bai-gen Zhang; Ji-wei Zhang
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.